Clinical Trials in Chronic Lymphocytic Leukaemia (CLL)


Target mechanism of investigative drug


Title of clinical trial






This trial is looking at how idelalisib works for people with chronic lymphocytic leukaemia (CLL). It is for people whose CLL came back or got worse whilst taking ibrutinib, or they are not able to have inbrutinib and they have been treated for their CLL before but it has come back or got worse.


More details




This trial is comparing ibrutinib alongside rituximab with fludarabine, cyclophosphamide, rituximab and venetoclax for chronic lymphocytic leukaemia. This trial is for people who haven’t yet had treatment for their chronic lymphocytic leukaemia (CLL)


More details


This trial is for patients with untreated CLL, comparing the drug BGB-3111 with bendamustine and rituximab.

More details